GlassScriptPhysician profile
Jorge Luis Cabrera
NPI 1174669246
$3,420.78
in general payments reported to CMS, 2019-2025
34 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $333 · 2021: $451 · 2022: $428 · 2023: $819 · 2024: $343 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $556.96 | 2019-2025 | Wegovy, Saxenda |
| Amgen INC. | $381.26 | 2019-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $293.58 | 2019-2024 | |
| Abbvie INC. | $204.84 | 2021-2024 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $192.66 | 2020-2024 | Mounjaro, Trulicity |
| Edwards Lifesciences Corporation | $189.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $179.07 | 2019-2020 | |
| Abbott Laboratories | $130.86 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $119.01 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Karl Storz Endoscopy-America | $105.83 | 2019 | |
| Boston Scientific Corporation | $100.09 | 2023-2024 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.46 | 2019-2023 | Xifaxan |
| Radius Health, INC. | $89.33 | 2019-2024 | Tymlos |
| Mannkind Corporation | $81.76 | 2019 | |
| Glaxosmithkline, LLC. | $64.88 | 2019-2024 | Trelegy Ellipta, Arexvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $57.03 | 2019-2023 | |
| Fidia Pharma USA INC. | $54.25 | 2023-2025 | Triluron, Hymovis, Hyalgan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.82 | 2019-2022 | |
| Dexcom, INC. | $50.58 | 2021-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $40.98 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $39.98 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $35.27 | 2024 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $33.79 | 2019 | |
| Corcept Therapeutics | $32.60 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $32.18 | 2021-2023 | Xarelto |
| Tolmar, INC. | $28.95 | 2023-2024 | |
| Insulet Corporation | $26.05 | 2025 | Omnipod |
| Lundbeck LLC | $25.96 | 2019 | |
| Exact Sciences Corporation | $25.81 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $22.69 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.90 | 2022 | |
| Shire North American Group INC | $13.95 | 2019 | |
| Allergan, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.